A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
CompletedNCT01749410
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.
Study details
- Conditions
- Chronic Migraine, Headaches
- Interventions
- Biological: onabotulinumtoxinA
- Sponsor
- Allergan
- Start date
- 2013-05
- Primary completion
- 2014-05
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * 15 or more headache days over a 30 day period * A minimum of 7 treatment cycles with onabotulinumtoxinA Exclusion Criteria: * Any treatment cycle dose of onabotulinumtoxinA greater than 200 units
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01749410